{"id":5740,"date":"2022-03-03T11:25:57","date_gmt":"2022-03-03T08:25:57","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5740"},"modified":"2022-03-03T11:34:53","modified_gmt":"2022-03-03T08:34:53","slug":"dunya-saglik-orgutu-covid-19-ilac-rehberini-molnupiravir-icin-kosullu-oneriler-icerecek-sekilde-guncelledi","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/dunya-saglik-orgutu-covid-19-ilac-rehberini-molnupiravir-icin-kosullu-oneriler-icerecek-sekilde-guncelledi\/","title":{"rendered":"D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc COVID-19 \u0130la\u00e7 Rehberini Molnupiravir \u0130\u00e7in Ko\u015fullu \u00d6neriler \u0130\u00e7erecek \u015eekilde G\u00fcncelledi"},"content":{"rendered":"

\"\"Uluslararas\u0131 uzmanlardan olu\u015fan D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (WHO) Rehber Geli\u015ftirme Grubu, antiviral ila\u00e7 molnupiraviri a\u011f\u0131r olmayan COVID-19’lu ve hastaneye yatma riski y\u00fcksek hastalara ko\u015fullu olarak \u00f6neriyor. S\u00f6z konusu rehber BMJ taraf\u0131ndan g\u00f6rsel olarak \u00f6zetlendi<\/strong>.<\/p>\n

WHO, COVID-19 tedavisine ili\u015fkin rehberini, yeni bir antiviral ila\u00e7 olan molnupiravir hakk\u0131nda ko\u015fullu \u00f6neriler i\u00e7erecek \u015fekilde g\u00fcncelledi.<\/p>\n

Molnupiravir, COVID-19 tedavi rehberlerine dahil edilen ilk oral antiviral ila\u00e7t\u0131r. Yeni bir ila\u00e7 oldu\u011fu i\u00e7in g\u00fcvenlik verisi \u00e7ok azd\u0131r. WHO, potansiyel zararlar\u0131 azaltmak i\u00e7in di\u011fer stratejilerle birlikte ila\u00e7 g\u00fcvenli\u011fini aktif olarak izlemeyi \u00f6nermektedir.<\/p>\n

Endi\u015feler ve veri bo\u015fluklar\u0131 nedeniyle, molnupiravir yaln\u0131zca hastaneye yat\u0131\u015f riski en y\u00fcksek olan ve durumu ciddi olmayan COVID-19 hastalar\u0131na \u00f6nerilmektedir. Bunlar, COVID-19 a\u015f\u0131s\u0131 olmam\u0131\u015f ki\u015filer, ya\u015fl\u0131lar, imm\u00fcn yetmezli\u011fi olan ki\u015filer ve kronik hastal\u0131klar\u0131 olan ki\u015filerdir.<\/p>\n

\u00c7ocuklara, hamile ve emziren kad\u0131nlara ila\u00e7 verilmemelidir. Molnupiravir alan ki\u015filerin bir kontraseptif plan\u0131 olmal\u0131 ve sa\u011fl\u0131k bak\u0131m noktas\u0131nda gebelik testi ve kontraseptiflere eri\u015fimi sa\u011flanmal\u0131d\u0131r.<\/p>\n

Oral tablet \u015feklinde olan molnupiravir, hekim g\u00f6zetiminde, semptomlar\u0131n ba\u015flamas\u0131ndan sonraki 5 g\u00fcn i\u00e7inde kullan\u0131lacak \u015fekilde be\u015f g\u00fcn boyunca g\u00fcnde iki kez d\u00f6rt tablet (toplam 800 mg) olarak verilir. \u0130nfeksiyondan sonra m\u00fcmk\u00fcn oldu\u011fu kadar erken kullan\u0131ld\u0131\u011f\u0131nda hastaneye yat\u0131\u015f\u0131n \u00f6nlenmesine yard\u0131mc\u0131 olabilir.<\/p>\n

G\u00fcncel \u00f6neri, 4796 hastay\u0131 i\u00e7eren alt\u0131 randomize kontroll\u00fc \u00e7al\u0131\u015fman\u0131n yeni verilerine dayanmaktad\u0131r. Bu, \u015fimdiye kadar bu ila\u00e7la ilgili elde edilen en b\u00fcy\u00fck veri setidir.<\/p>\n

BMJ’nin Rehber \u00d6zeti \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n

WHO A\u00e7\u0131klamas\u0131 \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Uluslararas\u0131 uzmanlardan olu\u015fan D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (WHO) Rehber Geli\u015ftirme Grubu, antiviral ila\u00e7 molnupiraviri a\u011f\u0131r olmayan COVID-19’lu ve hastaneye yatma riski y\u00fcksek hastalara ko\u015fullu olarak \u00f6neriyor. S\u00f6z konusu rehber BMJ taraf\u0131ndan g\u00f6rsel olarak \u00f6zetlendi. WHO, COVID-19 tedavisine ili\u015fkin rehberini, yeni bir antiviral ila\u00e7 olan molnupiravir hakk\u0131nda ko\u015fullu \u00f6neriler i\u00e7erecek \u015fekilde g\u00fcncelledi. Molnupiravir, COVID-19 tedavi rehberlerine dahil edilen ilk oral antiviral ila\u00e7t\u0131r. Yeni bir ila\u00e7 oldu\u011fu i\u00e7in g\u00fcvenlik verisi \u00e7ok azd\u0131r. WHO, potansiyel zararlar\u0131 azaltmak i\u00e7in di\u011fer stratejilerle birlikte ila\u00e7 g\u00fcvenli\u011fini aktif olarak izlemeyi \u00f6nermektedir. Endi\u015feler ve veri bo\u015fluklar\u0131 nedeniyle, molnupiravir yaln\u0131zca hastaneye yat\u0131\u015f riski en y\u00fcksek olan ve durumu ciddi olmayan […]<\/p>\n","protected":false},"author":4,"featured_media":5741,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5740"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5740"}],"version-history":[{"count":2,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5740\/revisions"}],"predecessor-version":[{"id":5743,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5740\/revisions\/5743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5741"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}